SEC Form 4 · accession 0000315066-15-003308
Blueprint Medicines Corp · BPMC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Nov 16, 2015 | S | 23,785 | $20.78 | D | 1,173,496 | I | Shares held by persons and entities whose shares are subject to reporting by the undersigned. |
| Common StockF2 | Nov 16, 2015 | S | 1,820 | $21.41 | D | 1,171,676 | I | Shares held by persons and entities whose shares are subject to reporting by the undersigned. |
| Common Stock | Nov 16, 2015 | S | 300 | $22.02 | D | 1,171,376 | I | Shares held by persons and entities whose shares are subject to reporting by the undersigned. |
| Common StockF3 | Nov 16, 2015 | S | 2,779 | $20.77 | D | 1,168,597 | I | Shares held by persons and entities whose shares are subject to reporting by the undersigned. |
Table II — derivative securities
Explanation of responses
- F1The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $20.00 to $20.99. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F2The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $21.01 to $21.82. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $20.08 to $20.90. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Remarks
Remark 1: Edward C. Johnson 3d is a Director and the Chairman of FMR LLC and Abigail P. Johnson is a Director, the Vice Chairman, the Chief Executive Officer and the President of FMR LLC. Members of the family of Edward C. Johnson 3d, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of Edward C. Johnson 3d and Abigail P. Johnson is c/o FMR LLC, 245 Summer Street, Boston, MA 02110. Remark 2: The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the undersigned are the beneficial owners of any securities reported herein.